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CI 17.9, 29.2). SARDs were more common in females than 
in males across all provinces. There was a slightly higher 
prevalence among those living in urban compared to rural 
areas of Alberta (rate difference 14.4, 95 % CI 8.6, 20.1) 
and Saskatchewan (rate difference 13.8, 95 % CI 1.0, 26.6). 
Our results provide population-based prevalence estimates 
of pediatric SARDs in four Canadian provinces.
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Abstract To estimate systemic autoimmune rheumatic 
disease (SARD) prevalence using administrative data for 
pediatric populations in four Canadian provinces. Physi-
cian billing claims and inpatient hospitalizations from 
Alberta, Manitoba, Quebec, and Saskatchewan were used 
to define cases aged ≤18 years with a SARD diagnosis 
code in: one or more hospitalization, two or more physician 
visits within 2 years and at least 2 months apart, or one or 
more physician visit to a rheumatologist. Estimates ranged 
from 15.9/100,000 in Quebec [95 % confidence interval 
(95 % CI) 14.1, 18.0] to 23.0/100,000 in Manitoba (95 % 
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Population-based administrative health databases are being 
increasingly used for outcomes research and surveillance 
in chronic rheumatic disease [1–4], but most studies have 
focused on adult populations. We used provincial admin-
istrative data to estimate systemic autoimmune rheumatic 
disease (SARD) prevalence in the pediatric population of 
four Canadian provinces: Alberta, Manitoba, Quebec, and 
Saskatchewan.
Methods
This study used physician billing claims and hospitaliza-
tion records to ascertain SARDs cases. Physician services 
are recorded provincially for remuneration purposes and 
contain a single diagnosis, while hospitalization records 
contain up to 25 diagnoses, all of which were reviewed for 
SARDs (Table 1). Diagnoses are coded according to the 
World Health Organization’s International Classification of 
Diseases (ICD), version 9, ICD 9-CM, or ICD 10 Canadian 
version (10-CA).
Data from the provinces spanned the following periods: 
Alberta 1994–2007, Manitoba 1995–2009, Quebec 1994–
2003, and Saskatchewan 1998–2007. We used a case ascer-
tainment algorithm previously validated in adult SARDs 
[5], which defines cases as one or more of: (a) ≥1 hospi-
talization with a SARD diagnosis recorded anywhere on 
the hospital discharge record, (b) ≥2 physician visits with a 
SARD diagnosis at least 2 months apart but within a 2-year 
period, (c) ≥1 physician visit to a rheumatologist with a 
SARD diagnosis. A subject was included in our estimates if 
he/she remained in the province and was ≤18 years of age 
as of the end of the study interval. Cases that satisfied more 
than one definition were only counted once in prevalence 
estimates.
Statistics Canada Census data from the last year of 
the study period for each province were used to estimate 
prevalence per 100,000 residents aged ≤18 years. Urban 
regions were defined as census metropolitan (population 
>100,000) and census agglomeration (population >10,000 
but <100,000) areas and were determined by residence 
code in Saskatchewan and postal code in Alberta, Que-
bec, and Manitoba. All other areas were considered rural. 
Residence codes in Saskatchewan are five digit numeric 
codes that uniquely identify each city, town, village, rural 
municipality, and First Nation. We did not provide esti-
mates of individual SARDs (systemic lupus, scleroderma, 
or inflammatory myopathies), because we were not able 
to distinguish these by diagnosis code for Manitoba and 
Saskatchewan.
Results
Table 2 presents the crude SARDs prevalence estimates 
per 100,000 individuals ≤18 years. The overall pediat-
ric SARDs prevalence estimates per 100,000 were 19.6 in 
Alberta [95 % confidence interval (95 % CI) 16.7, 22.9], 
23.0 in Manitoba (95 % CI 17.9, 29.2), 15.9 in Quebec 
(95 % CI 14.1, 18.0), and 20.9 in Saskatchewan (95 % CI 
15.6, 27.5). The 95 % CI of the estimated differences in 
rates between Manitoba and Saskatchewan, Manitoba and 
Alberta, Saskatchewan and Alberta, and Saskatchewan and 
Quebec were too wide for definitive conclusions; however, 
there was evidence for a difference in rates between Que-
bec versus Manitoba (−7.1 per 100,000, 95 % CI −12.9, 
−1.3), and Quebec versus Alberta (−3.7, 95 % CI −7.2, 
−0.1). SARDs were more common in females than in 
males across all provinces. There was a slightly higher 
prevalence among those living in urban compared to rural 
areas of Alberta (rate difference 14.4, 95 % CI 8.6, 20.1) 
and Saskatchewan (rate difference 13.8, 95 % CI 1.0, 26.6). 
The rate difference intervals for urban compared to rural 
areas of residence in Manitoba and Quebec had CIs that 
were too wide for definitive conclusions.
Discussion
We calculated population-based estimates of pediatric 
SARDs prevalence in four Canadian provinces, with esti-
mates suggesting about 2 SARDs cases per 10,000 resi-
dents aged 18 or less. We did not provide estimates of 
individual SARDs because we were not able to distinguish 
these by diagnosis code for Manitoba and Saskatchewan. 
Pediatric SARDs prevalence estimates from our study are 
higher than those reported by the only pediatric rheuma-
tology clinic in Saskatchewan, Canada [6], and prevalence 
rates have not been previously reported for Alberta, Mani-
toba, or Quebec. Our case definition aims for adequate 
sensitivity, which may have resulted in lower specificity 
than clinic-based data, and consequently misclassification 
of SARDs cases leading to a higher prevalence rate. For 
example, during the time period of this study in Saskatch-
ewan, pediatric rheumatology billed as general pediatrics, 
and two general pediatricians could not bill for the same 
diagnosis code for the same patient on the same day, which 
may have contributed to misclassification of administrative 
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data diagnoses. On the other hand, a clinic-based estimate 
could potentially underestimate prevalence (if SARD cases 
do not come to the attention of the pediatric rheumatology 
clinic).
In reports based on clinic data in BC, 3–6 % of pediatric 
rheumatology patients seen in follow-up are SARDs cases 
[7]. The most common pediatric SARD is systemic lupus 
erythematosus (SLE), which accounts for about a third of 
SARDs cases, while juvenile dermatomyositis accounts 
for approximately another fifth. SARD prevalence across 
regions may be driven in part by differences in race/ethnic-
ity. A study from British Columbia, Canada [8] using clini-
cal records suggested a prevalence of 3.3 cases per 100,000 
in non-First Nations children, with a much higher rate in 
First Nations (Native North American) children of 8.8 
cases per 100,000. SLE is more frequent (and diagnosed 
at a younger age) in non-white individuals, specifically in 
Hispanics, blacks (both African-Americans and Afro-Car-
ibbeans), Asians, and persons of Native North American 
origin [9–11]. Within the provinces studied, Manitoba and 
Saskatchewan have more residents of Aboriginal status. 
Aboriginal status includes Native North American, Métis 
(part European and part Native North American), and Inuit 
(from Northern Canada). In Manitoba and Saskatchewan, 
15.8–14.9 % of the population are Aboriginal, respectively, 
by self-report according to Statistics Canada, compared 
to 5.8 % in Alberta and 1.5 % in Quebec [12]. The higher 
prevalence estimates from Manitoba and Saskatchewan 
may be driven by the large number of Aboriginal residents 
in these provinces. Our study was not able to examine 
the relationship between Aboriginal status and pediatric 
SARDs prevalence rates directly because we did not have a 
reliable indicator of Aboriginal status in any province other 
than Alberta.
We observed higher rates of SARDs in pediatric resi-
dents of urban Alberta compared to rural areas in that 
province. Although data in Saskatchewan suggested a 
similar trend, due to the low numbers of male cases, the 
differences were not statistically significant for rural and 
urban regions when stratified by sex. Interestingly, at least 
one report has also suggested a higher occurrence also for 
juvenile idiopathic arthritis in urban populations [13]. The 
reasons for such a phenomenon are unknown. It is possible 
that an apparent higher disease prevalence in urban versus 
Table 1  ICD 9 and corresponding ICD 10-CA codes included as SARDs
710.6 and 710.7 are not used in ICD 9
ICD 9 code Diagnoses ICD 10-CA code Diagnoses
710.0 Systemic lupus erythematosus M32.1 Systemic lupus erythematosus,  
with organ or system involvementDisseminated lupus erythematosus
Libman–Sacks disease M32.8 Other forms of systemic lupus erythematosus
M32.9 Systemic lupus erythematosus, unspecified





710.2 Sicca syndrome M35.0 Sicca syndrome (Sjögren)
Keratoconjunctivitis sicca
Sjögren’s disease
710.3 Dermatomyositis M33.x Dermatopolymyositis
Poikilodermatomyositis
Polymyositis with skin involvement M36.0 Dermato(poly)myositis in neoplastic disease
710.4 Polymyositis M33.x Dermatopolymyositis
M36.0 Dermato(poly)myositis in neoplastic disease
710.5 Eosinophilia myalgia syndrome None None
Toxic oil syndrome
710.8 Other specified diffuse diseases of connective tissue M35.8 Other specified systemic involvement of  
connective tissueMultifocal fibrosclerosis (idiopathic) NEC
Systemic fibrosclerosing syndrome
710.9 Unspecified diffuse connective tissue disease M35.9 Systemic involvement of connective  
tissue, unspecifiedCollagen disease NOS
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rural areas is at least partially linked to access to care, since 
cases must seek medical attention in order to be included in 
the prevalence estimates.
In general, SARDs are more common in females than 
in males. For example, in children, SLE has been reported 
to have a prevalence ratio of about four or five females to 
every male case [14–16], and in juvenile dermatomyositis 
at 2.2 to 1 [17]. The female to male ratios that we estimated 
are consistent with this phenomenon.
Compared to estimates in adults, prevalence estimates 
for pediatric rheumatic diseases are relatively rare. Accu-
rate estimates of rates of pediatric-onset chronic disease 
are critical to determine the public health impact of these 
disorders. Much of the existing literature on outcomes in 
patients with rheumatic disease is based on data from ter-
tiary care centers, which is limited by sample size and the 
potential for selection bias. An alternative approach is the 
creation of relatively large population-based cohorts from 
administrative databases.
Prevalence estimates were based on algorithms previ-
ously developed in the adult population [5, 18] that have 
not been validated in the pediatric setting. Recent guide-
lines [19] recommend age-specific validation studies to 
account for differences in the sensitivity and specificity of 
case finding algorithms across ages, as there is the potential 
for misclassification of cases, which may result in biased 
prevalence estimates. Additionally, some physicians may 
code cases for which they were asked to “rule out” a diag-
nosis as that diagnosis, which would also contribute to mis-
classification of SARDs cases, increasing prevalence esti-
mates. It is not clear how shadow billing and the alternate 
funding plans (salary based) through which many Canadian 
pediatric rheumatologists are currently reimbursed would 
affect prevalence estimates, and we could not account for 
this. Additionally, in some provinces, pediatric rheuma-
tologists bill as general pediatricians or internists, and we 
would not have captured these individuals as rheumatolo-
gists in our algorithm. A validation study was beyond the 
scope of this work. Our analysis also did not account for 
potential imperfect sensitivity or specificity of the informa-
tion contained in the databases; latent class models have 
been used for SARD estimation in adults [4, 20], but their 
use has been limited for prevalence estimation in pediat-
ric populations, since these methods are difficult to apply 
in settings where the absolute number of cases is relatively 
small (as is the case for pediatric SARDs).
Despite some limitations, our prevalence estimates pro-
vide population-based prevalence estimates of SARDs in the 
Canadian pediatric population. These data can provide useful 
information about potential regional and demographic varia-
tions in disease estimates. Pediatric validation studies will be 
important to assess the quality of these estimates and deter-
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